Subscribe
360b-shutterstock-com-2-
360b / Shutterstock.com
6 August 2015Americas

European Commission approves Pfizer’s buyout of Hospira

The European Commission has approved US pharmaceutical company Pfizer’s $17 billion acquisition of Hospira, a move that will see Pfizer acquire the drugs company’s biosimilar portfolio.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Pfizer’s Hospira buyout approved in Australia and Canada
18 August 2015   Pfizer’s $17 billion buyout of Hospira has been approved in Canada and Australia after the countries’ competition bureaus approved the deal.
Americas
US and Brazil clear path for Pfizer’s Hospira buyout
26 August 2015   Pfizer’s buyout of Hospira, which is set to boost Pfizer’s biosimilars portfolio but has been the subject of anti-competition concerns, will be completed next month after gaining final approval.
Big Pharma
European Commission proposes ‘single market’ for meds
27 April 2023   Proposals include new regulatory protection periods for innovative drugs | Changes are aimed at improving patient access to therapeutics and boosting the EU pharma industry.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Pfizer’s Hospira buyout approved in Australia and Canada
18 August 2015   Pfizer’s $17 billion buyout of Hospira has been approved in Canada and Australia after the countries’ competition bureaus approved the deal.
Americas
US and Brazil clear path for Pfizer’s Hospira buyout
26 August 2015   Pfizer’s buyout of Hospira, which is set to boost Pfizer’s biosimilars portfolio but has been the subject of anti-competition concerns, will be completed next month after gaining final approval.
Big Pharma
European Commission proposes ‘single market’ for meds
27 April 2023   Proposals include new regulatory protection periods for innovative drugs | Changes are aimed at improving patient access to therapeutics and boosting the EU pharma industry.

More on this story

Americas
Pfizer’s Hospira buyout approved in Australia and Canada
18 August 2015   Pfizer’s $17 billion buyout of Hospira has been approved in Canada and Australia after the countries’ competition bureaus approved the deal.
Americas
US and Brazil clear path for Pfizer’s Hospira buyout
26 August 2015   Pfizer’s buyout of Hospira, which is set to boost Pfizer’s biosimilars portfolio but has been the subject of anti-competition concerns, will be completed next month after gaining final approval.
Big Pharma
European Commission proposes ‘single market’ for meds
27 April 2023   Proposals include new regulatory protection periods for innovative drugs | Changes are aimed at improving patient access to therapeutics and boosting the EU pharma industry.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent